Advertisement
Singapore markets closed

  • Straits Times Index

    3,367.90
    +29.33 (+0.88%)
     

  • S&P 500

    5,480.52
    +5.43 (+0.10%)
     

  • Dow

    39,150.56
    -18.96 (-0.05%)
     

  • Nasdaq

    17,923.97
    +44.68 (+0.25%)
     

  • Bitcoin USD

    61,974.04
    -970.42 (-1.54%)
     

  • CMC Crypto 200

    1,310.13
    -34.37 (-2.56%)
     

  • FTSE 100

    8,121.20
    -45.56 (-0.56%)
     

  • Gold

    2,333.70
    -5.20 (-0.22%)
     

  • Crude Oil

    83.42
    +0.04 (+0.05%)
     

  • 10-Yr Bond

    4.4460
    -0.0330 (-0.74%)
     

  • Nikkei

    40,074.69
    +443.63 (+1.12%)
     

  • Hang Seng

    17,769.14
    +50.53 (+0.29%)
     

  • FTSE Bursa Malaysia

    1,597.96
    -0.24 (-0.02%)
     

  • Jakarta Composite Index

    7,125.14
    -14.48 (-0.20%)
     

  • PSE Index

    6,358.96
    -39.81 (-0.62%)
     

Ultragenyx: Q1 Earnings Snapshot

Associated Press Finance
·1-min read

NOVATO, Calif. (AP) — NOVATO, Calif. (AP) — Ultragenyx Pharmaceutical Inc. (RARE) on Thursday reported a loss of $170.7 million in its first quarter.

On a per-share basis, the Novato, California-based company said it had a loss of $2.03.

The results fell short of Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was for a loss of $1.72 per share.

The biotechnology company posted revenue of $108.8 million in the period, also falling short of Street forecasts. Nine analysts surveyed by Zacks expected $114.4 million.

Ultragenyx expects full-year revenue in the range of $500 million to $530 million.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RARE at https://www.zacks.com/ap/RARE